胺作为一种替代麻醉剂,用于增加电治疗期间的发作持续时间:一项回顾性观察性研究
Sarara Mutoh1, Michiko Kinoshita, Yuki Maeda
1From the Department of Anesthesiology, Tokushima University Hospital, Tokushima, Japan.
The journal of ECT
|December 18, 2023
概括
在电疗法 (ECT) 期间切换到胺麻醉,有效地延长了发作持续时间,患者的发作低于最佳. 这种方法可以提高ECT的疗效,但需要仔细监测循环变化和并发症.
科学领域:
- 神经科学是一个神经科学.
- 麻醉学 麻醉学
- 精神病学是一个精神病学.
背景情况:
- 电疗法 (ECT) 是严重精神疾病的重要治疗方法.
- 在ECT期间的低于最佳的发作持续时间可能会损害治疗的有效性.
- 确定优化发作持续时间的策略对于改善ECT结果至关重要.
研究的目的:
- 研究使用胺麻醉剂来增加ECT患者的持续时间的疗效和安全性.
- 评估切换到胺胺对发作参数,刺激要求和血液动力学变异性的影响.
主要方法:
- 对33名因在ECT期间发作不足而接受胺麻醉的患者的回顾性分析.
- 在麻醉切换前后评估脑电图 (EEG) 和运动持续时间,刺激能量,血液动力学反应以及麻醉后并发症.
主要成果:
- 胺麻醉显著延长了EEG (平均差异:34.6秒) 和运动的持续时间 (平均差异:26.6秒).
- 在切换ketamine后观察到刺激剂量的显著降低 (平均差异:-209.5mC).
- 随着胺使用,血动力学变异性 (静脉压和心率) 的增加和头痛的更高发病率被观察到.
结论:
- 胺作为一种有效的麻醉替代品,可以在ECT中增加发作持续时间,当发生低于最佳发作时.
- 胺的使用需要对循环管理和潜在的后并发症保持高度警.
- 年龄被确定为与ECT期间次优发作相关的因素.
相关概念视频
Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
Parenteral Anesthetics: Overview
130
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
130
Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
Antiepileptic Drugs: GABAergic Pathway Potentiators
413
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
413
Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
Depolarizing Blockers: Pharmocokinetics
327
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
327


